Ceftazidime-avibactam (CAZ-AVI), a novel beta-lactam/beta-lactamase inhibitor, plays a crucial role in treating infections caused by difficult-to-treat CRE, particularly those involving OXA-48 and KPCs [30]. Here, LACTB is linked to infection.